TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

COLY-MYCIN M

COLISTIMETHATE SODIUM
Infectious Disease Approved 1970-06-04
1
Indication
--
Phase 3 Trials
55
Years on Market

Details

Status
Prescription
First Approved
1970-06-04
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: COLISTIMETHATE SODIUM

COLY-MYCIN M Approval History

Loading approval history...

What COLY-MYCIN M Treats

1 indications

COLY-MYCIN M is approved for 1 conditions since its original approval in 1970. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Infections
Source: FDA Label

Drugs Similar to COLY-MYCIN M

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

COLY-MYCIN M FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Coly-Mycin M Parenteral is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Coly-Mycin M Parenteral has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Coly-Mycin M Parenteral may be used to initiate t...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.